Spencer Feldman

Brukinsa plus R-CHOP demonstrated high efficacy and durable responses in double-expressor lymphoma, with manageable safety, supporting further phase 3 trials.

Verzenio plus Faslodex improved progression-free survival in HR+/HER2– advanced breast cancer after CDK/6i failure, with a manageable safety profile.

Enhertu improved overall survival versus chemotherapy in HER2-positive metastatic gastric cancer, prompting an interim analysis and potential regulatory approvals.

The first patient with small cell lung cancer has been dosed in a trial of peluntamig (PT217) combined with chemotherapy.

Chemoradiation improves survival in cervical cancer patients, but benefits may decline after age 80, according to a study using SEER data.

Datroway demonstrated durable antitumor activity and an acceptable safety profile in advanced NSCLC with actionable genomic alterations, including EGFR and ALK subgroups.

Zongertinib, an investigational treatment for HER2-mutant advanced NSCLC, has received FDA priority review, showing positive results and favorable safety.

Ficerafusp alfa enters phase 2/3 trial for recurrent/metastatic head and neck cancer, evaluating its combination with Keytruda for first-line treatment.

SBRT improved local progression-free survival over RFA in small recurrent HCC, particularly in tumors 2 cm or less.

The addition of nab-paclitaxel to gemcitabine and cisplatin did not improve survival in advanced biliary tract cancer.

Neuropathy, skin rash, and hyperglycemia following enfortumab vedotin treatment were associated with improved PFS in metastatic urothelial carcinoma.

The FDA accepted Regeneron’s BLA resubmission for linvoseltamab in relapsed or refractory multiple myeloma, with a decision expected by July 10, 2025.

Breyanzi has shown significant efficacy and durable responses in patients with marginal zone lymphoma.

Tagrisso was linked to higher cardiac risks in patients with EGFR-mutant NSCLC, including a four-fold rise in cardiac events and reduced overall survival.

Dr. Marwan G. Fakih discussed the FDA approval of Lumakras with Vectibix for third-line treatment of KRAS G12C-mutated metastatic colorectal cancer.

A study found no significant HRQOL differences between Erleada-based therapies and ADT plus AAP for advanced castration-sensitive prostate cancer.

Alecensa weight gain is underreported in ALK+ NSCLC trials, highlighting the need for increased awareness and proactive management of this side effect.

A phase 3 trial is evaluating ASP-1929 photoimmunotherapy plus Keytruda in first-line treatment for recurrent head and neck squamous cell carcinoma.

From the reveal of NBA star Dwyane Wade’s cancer surgery to a Bachelorette star on her husband’s cancer diagnosis, here is this week’s top cancer news.

Galinpepimut-S therapy showed specific T-Cell immune responses for patients with acute myeloid leukemia in remission following second-line salvage therapy.

Brukinsa had a lower risk of disease progression or death versus Imbruvica, as well as a more favorable safety profile, in R/R CLL and SLL.

Adults with primary primary appendiceal adenocarcinoma face a higher risk of developing a second primary cancer, including colorectal and prostate cancers.

Missing weekly cisplatin cycles was associated with worse OS in patients with head and neck cancers, particularly for those with p16-negative tumors.

A phase 2a trial of IMM-1-104 plus chemotherapy demonstrated efficacy and tolerability in first- and second-line pancreatic cancer.

PH284 increased feelings of hunger and was safe in patients with cancer cachexia, which results in significant weight loss.

A diet high in omega-3 fatty acids and low in omega-6 fatty acids, taken with fish oil, reduced the Ki-67 index in men with prostate cancer on active surveillance.

Elinzanetant significantly reduced the frequency and severity of hot flashes in women with breast cancer who were undergoing hormone therapy.

Adding hyperthermic intraperitoneal chemotherapy to surgery did not improve progression-free survival in platinum-sensitive recurrent ovarian cancer.

CURE spoke with an expert about the potential positive effects of radiation therapy for patients with hepatocellular carcinoma.

The FDA has granted fast track designation for abenacianine to help surgeons better visualize lung tumors during minimally invasive surgery.